The paper's citation list
No. | The paper's citation list |
|---|
1 | Circulating bile acid profiles characteristics and the potential predictive role in clear cell renal cell carcinoma progression. 2025;26: doi: 10.1186/s12882-025-04142-y |
2 | Shutting those revolving doors. 2023;28:101106 doi: 10.1016/j.aohep.2023.101106 |
3 | MASLD co-aggregates with HCC in families-names change, fa(c)ts remain. 2023; doi: 10.20517/2394-5079.2023.110 |
4 | How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?. 2025;182:1651 doi: 10.1111/bph.70003 |
5 | Editorial - Reflecting on three years of M&TOD - Where we are and where we are going. 2024;4: doi: 10.20517/mtod.2024.65 |
6 | Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies. 2023;188 doi: 10.37349/edd.2023.00026 |
7 | Does an Aspirin a Day Take the MASLD Away?. 2024;41:2559 doi: 10.1007/s12325-024-02885-y |
8 | Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes. 2024;2:10006 doi: 10.70322/fibrosis.2024.10006 |
9 | TPGS-modified Chitosan Nanoparticles of EGFR Inhibitor: Physicochemical and In vitro Evaluation against HepG2 Cell Lines. 2025;22:465 doi: 10.2174/0115672018268315231206045504 |
10 | Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease. 2024;4: doi: 10.20517/mtod.2024.42 |
11 | Metabolism, sex, and what lies beyond the scalpel in MASLD. 2025;5: doi: 10.20517/mtod.2025.05 |
12 | Cytokeratin 18 in nonalcoholic fatty liver disease: value and application. 2024;24:1009 doi: 10.1080/14737159.2024.2413941 |
13 | Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990–2021. 2025; doi: 10.14309/ajg.0000000000003288 |
14 | Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. 2025; doi: 10.1016/j.tem.2024.12.009 |
